Immunovaccine to Present at 6th Annual Biotech Showcase Conference

Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX
VENTURE:IMV), a clinical stage vaccine and immunotherapy company, today
announced that the Company will present at the 6th Annual Biotech Showcase
Conference. The conference will take place January 13-15, 2014 at the Parc 55
Wyndham San Francisco Union Square Hotel. 


Details of Immunovaccine's presentation are as follows:



Event:         Biotech Showcase(TM) 2014 Conference                         
Date:          Monday, January 13, 2014                                     
Time:          9:00 a.m.                                                    
Location:      Room Mission II, Parc 55 Wyndham San Francisco Union Square  
               Hotel                                                        



Marc Mansour, Ph.D., Chief Operating Officer of Immunovaccine, will present a
corporate update including the latest developments for the Company's two
clinical-stage cancer vaccines, as well as its proprietary DepoVax(TM) vaccine
adjuvanting delivery platform. 


Immunovaccine expects three trials to be initiated in 2014 with its cancer
immunotherapies, the largest of which is a randomized Phase II trial of
DPX-Survivac in ovarian cancer being sponsored and conducted by Canada's NCIC
Clinical Trials Group (NCIC CTG). The trial is expected to begin enrolling the
first of its 250 patients in 2014. Additionally, researchers at the University
of Rome have announced plans to initiate a Phase II trial of DPX-Survivac in
glioblastoma (brain cancer) patients in the first half of 2014. A third trial,
using DPX-0907 to treat breast and ovarian cancer, is planned for initiation at
Busto Arsizio Hospital in Milan.


About Ovarian Cancer

Ovarian cancer accounts for more deaths than any other gynecologic cancer.
Symptoms do not occur until it is in the later stages of the disease, reducing
the chance for successful treatment and remission. It kills more than 100,000
women annually around the world. Improved surgical techniques have helped to
reduce the rate of recurrence according to some studies, but the average life
expectancy of newly diagnosed ovarian cancer patients is less than four years. 


About Glioblastoma

Glioblastoma, the most common form of brain cancer, is a fast-growing tumor type
that develops from astrocytes, a type of glial cell present in the brain. The
National Cancer Institute estimates that more than 23,000 Americans will be
diagnosed with brain and other nervous system tumors in 2013. Glioblastoma
accounts for approximately 15 percent of all brain tumors. The current standard
of care for glioblastoma patients calls for patients to receive maximum surgical
resection combined with radiation and concomitant and adjuvant temozolomide
therapy. Newly diagnosed glioblastoma patients have a median overall survival of
less than 24 months.


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvant to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. 


Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, including information regarding the use of
proceeds of the financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Operating Officer
[phone]
[e-mail]


Immunovaccine, Inc.
Vida Strategic Partners (media)
Tim Brons
[phone]
[e-mail]
www.imvaccine.com